Device-therapy in chronic heart failure: Cardiac contractility modulation versus cardiac resynchronization therapy.
CCM
CIED
CRT
Chronic heart failure
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
29 Sep 2024
29 Sep 2024
Historique:
revised:
26
05
2024
received:
10
11
2023
accepted:
21
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
Cardiac implantable electrical devices such as cardiac resynchronization therapy with defibrillator (CRT-Ds) or cardiac contractility modulation (CCMs) are therapy options for patients with symptomatic heart failure (HF) and reduced left ventricular ejection fraction (LVEF) despite optimal medical treatment. As yet, a comparison between both devices has not been performed. The Mannheim Cardiac Resynchronization Therapy Registry (MARACANA) and the Mannheim Cardiac Contractility Modulation Observational Study (MAINTAINED) included all patients who received CRTs or CCMs in our medical centre between 2012 and 2021. For the present analysis, we retrospectively compared patients provided with either CRT-Ds (n = 220) or CCMs with additional defibrillators (n = 105) regarding New York Heart Association classification (NYHA), LVEF, tricuspid annular plane systolic excursion (TAPSE), QRS-width and other HF modification aspects after 12 months. Before implantation, CCM patients presented with lower LVEF (23.6 ± 6.2 vs. 26.3 ± 6.5%) and worse NYHA (3.03 ± 0.47 vs. 2.81 ± 0.48, both P < 0.05), compared with CRT-D patients. Follow-up improvements in NYHA (2.43 ± 0.67 vs. 2.28 ± 0.72), LVEF (30.5 ± 10.7 vs. 35.2 ± 10.5%) and TAPSE (17.2 ± 5.2 vs. 17.1 ± 4.8 to 18.9 ± 3.4 vs. 17.3 ± 3.6 mm, each P < 0.05) were comparable. The intrinsic QRS-width was stable with CCM (109.1 ± 18 vs. 111.7 ± 19.7 ms, P > 0.05), while the paced QRS-width with CRT-D after 12 months was lower than intrinsic values at baseline (157.5 ± 16.5 vs. 139.2 ± 16 ms, P < 0.05). HF hospitalizations occurred more often for CCM than CRT-D patients (45.7 vs. 16.8%/patient years, odds ratio 4.2, P < 0.001). Chronic heart failure patients could experience comparable 12-month improvements in functional status and ventricular reverse remodelling, with appropriately implanted CCMs and CRT-Ds. Differences in HF hospitalization rates may be due to the more advanced HF of CCM patients at implantation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : DZHK
Organisme : Deutsche Forschungsgemeinschaft
ID : 422681845
Organisme : Deutsche Forschungsgemeinschaft
ID : 394046768
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7‐11. doi:10.15420/cfr.2016:25:2
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599‐3726. doi:10.1093/eurheartj/ehab670
Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta‐adrenergic stimulation. Circulation 2004;109:1154‐1160. doi:10.1161/01.CIR.0000117254.68497.39
Lompré AM, Hajjar RJ, Harding SE, Kranias EG, Lohse MJ, Marks AR. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation 2010;121:822‐830. doi:10.1161/CIRCULATIONAHA.109.890954
Beuckelmann DJ. Contributions of Ca2+‐influx via the L‐type Ca2+‐current and Ca2+‐release from the sarcoplasmic reticulum to [Ca2+]i‐transients in human myocytes. Basic Res Cardiol 1997;92:105‐110.
Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+‐ATPase in failing and nonfailing human myocardium. Circ Res 1994;75:434‐442. doi:10.1161/01.res.75.3.434.
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021;42:3427‐3520. doi:10.1093/eurheartj/ehab364
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895‐e1032. doi:10.1161/CIR.0000000000001063
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877‐883. doi:10.1056/NEJMoa013474
Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail 2020;22:2349‐2369. doi:10.1002/ejhf.2046
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891‐975. doi:10.1002/ejhf.592
Vaillant C, Martins RP, Donal E, Leclercq C, Thébault C, Behar N, et al. Resolution of left bundle branch block‐induced cardiomyopathy by cardiac resynchronization therapy. J Am Coll Cardiol 2013;61:1089‐1095. doi:10.1016/j.jacc.2012.10.053
Strik M, Ploux S, Huntjens PR, Nguyên UC, Frontera A, Eschalier R, et al. Response to cardiac resynchronization therapy is determined by intrinsic electrical substrate rather than by its modification. Int J Cardiol 2018;270:143‐148. doi:10.1016/j.ijcard.2018.06.005
Moubarak G, Viart G, Anselme F. Acute correction of electromechanical dyssynchrony and response to cardiac resynchronization therapy. ESC Heart Fail 2020;7:1302‐1308. doi:10.1002/ehf2.12654
Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. Cardiac‐resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013;369:1395‐1405. doi:10.1056/NEJMoa1306687
Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J 2015;36:1983‐1989. doi:10.1093/eurheartj/ehv242
Hesselson AB. Cardiac contractility modulation: a technical review. J Innov Cardiac Rhythm Manag 2022;13:5205‐5218. doi:10.19102/icrm.2022.13102
Abraham WT. Cardiac resynchronization therapy and cardiac contractility modulation in patients with advanced heart failure: how to select the right candidate? Heart Fail Clin 2021;17:599‐606. doi:10.1016/j.hfc.2021.05.005
Kuschyk J, Kloppe A, Schmidt‐Schweda S, Bonnemeier H, Rousso B, Röger S. Cardiac contractility modulation: a technical guide for device implantation. Rev Cardiovasc Med 2017;18:1‐13. doi:10.3909/ricm0825
Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221‐1230. doi:10.1056/NEJMoa1608029
Leyva F, Israel CW, Singh J. Declining risk of sudden cardiac death in heart failure: fact or myth? Circulation 2023;147:759‐767. doi:10.1161/CIRCULATIONAHA.122.062159
Brunckhorst CB, Shemer I, Mika Y, Ben‐Haim SA, Burkhoff D. Cardiac contractility modulation by non‐excitatory currents: studies in isolated cardiac muscle. Eur J Heart Fail 2006;8:7‐15. doi:10.1016/j.ejheart.2005.05.011
Burkhoff D, Shemer I, Felzen B, Shimizu J, Mika Y, Dickstein M, et al. Electric currents applied during the refractory period can modulate cardiac contractility in vitro and in vivo. Heart Fail Rev 2001;6:27‐34. doi:10.1023/a:1009851107189
Imai M, Rastogi S, Gupta RC, Mishra S, Sharov VG, Stanley WC, et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol 2007;49:2120‐2128. doi:10.1016/j.jacc.2006.10.082
Borggrefe MM, Lawo T, Butter C, Schmidinger H, Lunati M, Pieske B, et al. Randomized, double blind study of non‐excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 2008;29:1019‐1028. doi:10.1093/eurheartj/ehn020
Butter C, Rastogi S, Minden HH, Meyhöfer J, Burkhoff D, Sabbah HN. Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Coll Cardiol 2008;51:1784‐1789. doi:10.1016/j.jacc.2008.01.036
Mohri S, Shimizu J, Mika Y, Shemer I, Wang J, Ben‐Haim S, et al. Electric currents applied during refractory period enhance contractility and systolic calcium in the ferret heart. Am J Physiol Heart Circ Physiol 2003;284:H1119‐H1123. doi:10.1152/ajpheart.00378.2002
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787‐1847. doi:10.1093/eurheartj/ehs104
Patel PA, Nadarajah R, Ali N, Gierula J, Witte KK. Cardiac contractility modulation for the treatment of heart failure with reduced ejection fraction. Heart Fail Rev 2020;26:217‐226. doi:10.1007/s10741‐020‐10017‐1
Zeller J, Hubauer U, Schober A, Schober A, Keyser A, Fredersdorf S, et al. Heart failure with recovered ejection fraction (HFrecEF): a new entity with improved cardiac outcome. Pacing Clin Electrophysiol: PACE 2021;44:2015‐2023. doi:10.1111/pace.14391.
Fudim M, Abraham WT, von Bardeleben RS, Lindenfeld J, Ponikowski PP, Salah HM, et al. Device therapy in chronic heart failure: JACC state‐of‐the‐art review. J Am Coll Cardiol 2021;78:931‐956. doi:10.1016/j.jacc.2021.06.040
Gheorghiade M, de Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005;96:11g‐17g. doi:10.1016/j.amjcard.2005.07.016
Goldstein SA, Mentz RJ, Hellkamp AS, Randolph TC, Fonarow GC, Hernandez A, et al. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. Clin Cardiol 2019;42:256‐263. doi:10.1002/clc.23135
Leyva F, Zegard A, Patel P, Stegemann B, Marshall H, Ludman P, et al. Timing of cardiac resynchronization therapy implantation. Europace 2023;25: doi:10.1093/europace/euad059
Butter C, Georgi C, Stockburger M. Optimal CRT implantation‐where and how to place the left‐ventricular Lead? Curr Heart Fail Rep 2021;18:329‐344. doi:10.1007/s11897‐021‐00528‐9
Codina P, Lupón J, Borrellas A, Spitaleri G, Cediel G, Domingo M, et al. Head‐to‐head comparison of contemporary heart failure risk scores. Eur J Heart Fail 2021;23:2035‐2044. doi:10.1002/ejhf.2352
Contaldi C, Vivo S, Martucci M, D'Onofrio A, Ammendola E, Nigro G, et al. Effects of cardiac contractility modulation therapy on right ventricular function: an echocardiographic study. Appl Sci 2022;12:7917.
Sharma A, Lavie CJ, Vallakati A, Garg A, Goel S, Lazar J, et al. Changes in parameters of right ventricular function with cardiac resynchronization therapy. Clin Cardiol 2017;40:1033‐1043. doi:10.1002/clc.22762
Phillips CA, Grood ES, Schuster B, Petrofsky JS. Left ventricular work and power: circumferential, radial and longitudinal components. Mathematical derivation and characteristic variation with left ventricular dysfunction. J Biomech 1982;15:427‐440. doi:10.1016/0021‐9290(82)90079‐3
Bazoukis G, Thomopoulos C, Tse G, Tsioufis K, Nihoyannopoulos P. Global longitudinal strain predicts responders after cardiac resynchronization therapy‐a systematic review and meta‐analysis. Heart Fail Rev 2022;27:827‐836. doi:10.1007/s10741‐021‐10094‐w
Kouzu H, Yuda S, Muranaka A, Doi T, Yamamoto H, Shimoshige S, et al. Left ventricular hypertrophy causes different changes in longitudinal, radial, and circumferential mechanics in patients with hypertension: a two‐dimensional speckle tracking study. Journal of the American Society of Echocardiography 2011;24:192‐199. doi:10.1016/j.echo.2010.10.020
Khazanie P, Hammill BG, Qualls LG, Fonarow GC, Hammill SC, Heidenreich PA, et al. Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD registry and ADHERE. Circ Heart Fail 2014;7:926‐934. doi:10.1161/CIRCHEARTFAILURE.113.000838
Kuschyk J, Falk P, Demming T, Marx O, Morley D, Rao I, et al. Long‐term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system. Eur J Heart Fail 2021;23:1160‐1169. doi:10.1002/ejhf.2202
Talha KM, Anker SD, Burkhoff D, Filippatos G, Lam CSP, Stone GW, et al. Role of cardiac contractility modulation in heart failure with a higher ejection fraction. J Card Fail 2022;28:1717‐1726. doi:10.1016/j.cardfail.2022.08.013